There are a number of companies, including Aspen, advancing cell therapies for Parkinson’s disease.

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric ...

Elaine currently serves on the boards of CytomX Therapeutics, HBM Healthcare Investments AG, and NextCure, is Chair of ...

According to a team of researchers, weaning or switching from milk to solid food in early life doesn’t just change what babies eat, it helps reprogram the gut’s immune defenses to mount faster and ...

Researchers at Karolinska Institutet have created the first detailed map showing how genetic activity is controlled in individual cells of the adult human brain and spinal cord. The study, published ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

Genetically engineering bacteria that live on our skin could prevent frostbite and hypothermia in extreme environments ...